Get started
Author

Zhongping Lily Mao

Observed names: Z Mao, Z. L. Mao, Z. Mao, Zhongping L. Mao, Zhongping Mao
ORCID: 0009-0009-1072-2414
Observed ORCID: 0009-0009-1072-2414
OpenAlex ID: A5033115889
The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry*
1996 · Shuqing Chen, Wen-Hwei Chou, et al. · Clinical Pharmacology & Therapeutics · 149
Pharmacokinetics of Novel Atrial‐Selective Antiarrhythmic Agent Vernakalant Hydrochloride Injection (RSD1235): Influence of CYP2D6 Expression and Other Factors
2008 · Zhongping L. Mao, Jeffery J. Wheeler, et al. · The Journal of Clinical Pharmacology · 38
Population Pharmacodynamics of IPX066: An Oral Extended‐Release Capsule Formulation of Carbidopa–Levodopa, and Immediate‐Release Carbidopa–Levodopa in Patients With Advanced Parkinson's Disease
2013 · Zhongping Mao, Ann Hsu, et al. · The Journal of Clinical Pharmacology · 29
PDF
A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al. · Clinical Cancer Research · 28
PDF
Pharmacokinetics of conivaptan hydrochloride, a vasopressin V1A/V2-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study
2009 · Zhongping Lily Mao, Dennis Stalker, et al. · Clinical Therapeutics · 17
Disposition and Mass Balance of [14C]Vernakalant After Single Intravenous and Oral Doses in Healthy Volunteers
2011 · Z. L. Mao, A. Alak, et al. · Drug Metabolism Letters · 13
Dose‐Response Analysis of the Effect of Carbidopa‐Levodopa Extended‐Release Capsules (IPX066) in Levodopa‐Naive Patients With Parkinson Disease
2015 · Zhongping Lily Mao, Nishit B. Modi · The Journal of Clinical Pharmacology · 12
PDF
Population pharmacokinetic–pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter
2011 · Zhongping Mao, Jeff J. Wheeler, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 9
Population Pharmacokinetics of Vernakalant Hydrochloride Injection (RSD1235) in Patients With Atrial Fibrillation or Atrial Flutter
2011 · Zhongping Lily Mao, Robert W. Townsend, et al. · The Journal of Clinical Pharmacology · 7
Mo1476 – Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects with Hepatic Impairment
2019 · Z Mao, Robert Martin, et al. · Gastroenterology · 1
Supplementary Figure S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Supplementary Figure S6 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Supplementary Table S5 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Supplementary Table S7 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Supplementary Methods S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Data from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Supplementary Table S6 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Supplementary Table S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Supplementary Table S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Supplementary Figure S7 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Supplementary Table S4 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Supplementary Figure S2 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Supplementary Figure S4 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Supplementary Figure S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Supplementary Table S2 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
2024 · James Brugarolas, Gregory Obara, et al.
Works count: 33
Citation count: 303
H-index: 8
I10-index: 7
Year
Topic
Type